Skip to main content

*Evolution of Ivermectin as a Drug of Choice for Prevention & Treatment of Covid-19: Dr. Surya Kant*

 New Delhi, 10th May, 2021: Covid-19 has emerged as an elusive foe, threatening mankind. Currently India is placed second in terms of number of reported cases which warrants newer therapeutic treatment options that are widely available,

affordable, effective and safe. There are newer drugs on the horizon which have been recommended though with very limited experience & devoid of enough data about safety and efficacy. These newer options are neither easily available nor affordable. “We have revisited some of the old molecules and have found ivermectin, originally introduced as an antihelminthic to be an effective, safe and affordable therapeutic option in Indian settings for prevention and treatment of COVID-19,” said Dr. Surya Kant, Professor and Head Department of Respiratory Medicine, at King George Medical University, Lucknow.

Dr Surya Kant, National Vice Chairman, IMA Academy of Medical Specialities, cited several studies in support of the effectiveness of Ivermectin in cases of SARs-CoV2 infection. According to a research paper published by Australia’s Monash University last year, the use of Ivermectin triggered 93% reduction in coronavirus load within 24 hours, a figure which reached 99.8% within 48 hours. As of now, 3.7 billion people have been treated with Ivermectin and hence proves to have profound safety profile.

Another research by Bangladesh Medical College Hospital, published last year, has shed a ray of light in portraying ivermectin’s astounding effectiveness as pre-exposure prophylaxis for COVID-19 among healthcare workers.

As per the recent findings from the results of 18 large-scale clinical trials on ivermectin in COVID-19 published by American Journal of Therapeutics, have found large, statistically significant reductions in death, time to clinical recovery, and time to viral clearance.

In July 2020, Dr. Surya Kant, with few other experts of India, wrote a white paper on ivermectin, which emphasized that ivermectin reduces the replication rate of the infection by several thousand times. It was only after this white paper when Uttar Pradesh government started using the drug. UP was the first state to use ivermectin, followed by which, government of West Bengal, Maharashtra, Assam & Kerala too included ivermectin in their protocol for the treatment of mild-moderate cases of COVID-19, no doubt this will benefit >40% of India’s population who belong to these states.  

Recently in May, 2021, even, AIIMS/ ICMR-COVID-19 protocol also suggested taking ivermectin for the treatment of COVID-19 when patients are under home isolation and also in all mild cases of the disease.

Currently more than 40 clinical trials are underway on ivermectin, including eight in India and not one has reported any major side effects yet. This includes the most prestigious institute in India i.e. AIIMS Delhi.

Said Dr. Surya Kant, Past President of Indian Chest Society: “ivermectin is a remarkable drug as it has proven to be highly effective in various stages of Covid Infection including pre- and post-exposure phase, the symptomatic phase and the pulmonary / inflammatory phase. In the recommended dosages, ivermectin is very safe. The drug, discovered way back in 1970, is already explored in several viral diseases like HIV, Dengue, Influenza and Zika.” 

He added: “In these days of shortages of drugs like Remdesivir, which on many occasions do not work, there is surplus supply of ivermectin in the market and the drug is easily available. It can be of great use to protect persons who came in close contact with a Covid-19 patient as well as in the treatment of asymptomatic and mild Covid patients.”

Currently there are many brands of ivermectin available in India like iverscab, vermact, scavista etc. Ivermectin has proven beneficial unlike many other drugs tested in Covid treatment. It is also a very cheap drug, which is easy to administer and is also profoundly safe.

Popular posts from this blog

छतरपुर जिला चिकित्सालय को मिलेअत्याधुनिक जांच उपकरण एस्सेल माइनिंग द्वारा सी-आर्म, रक्त जांच एवं अन्य उपकरण दान

 छतरपुर की स्वास्थ्य अधोसंरचना को मजबूत बनाने के ध्येय को आगे बढ़ाते हुए एस्सेल माइनिंग द्वारा शुक्रवार को छतरपुर जिला चिकित्सालय में अत्याधुनिक सी-आर्म इमेजिंग डिवाइस, हाई फ़्लो नैज़ल कैनुला समेत त्वरित रक्त जांच उपकरण एवं मोरचुरी फ्रीजर भेंट किया गया।  जिला कलेक्टर श्री संदीप जी आर ने फीता काटकर नई सुविधाओं का शुभारंभ किया। इस अवसर पर मुख्य चिकित्सा एवं स्वास्थ्य अधिकारी डॉ विजय पथोरिया एवं अस्पताल के अन्य अधिकारी-कर्मचारी उपस्थित रहे। नए उपकरणों के साथ छतरपुर जिला चिकित्सालय के सुविधाओं में वृद्धि होने के साथ ही हजारों नागरिकों को नई जाँचों का लाभ मिल सकेगा और त्वरित जांच प्राप्त हो सकेगी।कलेक्टर श्री श्री संदीप जी आर द्वारा इस अवसर पर अस्पताल परिसर में पौधा रोपण भी किया गया।  एस्सेल माइनिंग द्वारा लगातार छतरपुर जिले की स्वास्थ्य सेवाओं को उन्नत बनाने में सतत योगदान दिया जा रहा है। पूर्व में गुरुवार को कंपनी द्वारा बक्सवाहा के सामुदायिक स्वास्थ्य केंद्र को बड़ा मलहरा विधायक श्री प्रद्युम्न सिंह लोधी की उपस्थिति में एडवांस्ड लाइफ सपोर्ट एम्बुलेंस भेंट की गई। वेंटीलेटर जैसी सुविधाओं के सा

कर्नाटका बैंक ने इक्विपमेंट फाइनेंसिंग बिजनेस के लिये जेसीबी इंडिया लिमिटेड के साथ साझेदारी की

 कर्नाटका बैंक ने भारत में अर्थमूविंग एवं कंस्‍ट्रक्‍शन इक्विपमेंट बनाने वाली प्रमुख कंपनी जेसीबी इंडिया लिमिटेड के साथ एक समझौता ज्ञापन (एमओयू) पर हस्‍ताक्षर किये हैं। जेसीबी इंडिया लिमिटेड के साथ किए गए इस गठजोड़ की मदद से बैंक के एमएसएमई पोर्टफोलियो के तहत ऋण की सुविधा बेहतर होगी।   इस एमओयू के अंतर्गत, जेसीबी अपने फाइनेंस पार्टनर के तौर पर कर्नाटका बैंक को नॉमिनेट करेगी। परिणामस्‍वरूप, लोग/ठेकेदार/कंपनी/भागीदार कंपनियाँ/एलएलपी, आदि जेसीबी इंडिया लिमिटेड की उत्‍पाद श्रृंखला से विश्‍व-स्‍तरीय उपकरण खरीदने के लिये बैंक से प्रतिस्‍पर्द्धी ब्‍याज दरों पर लोन ले सकेंगे।    इस एमओयू पर हस्‍ताक्षर करने के बाद, कर्नाटका बैंक के प्रबंध निदेशक एवं सीईओ श्री महाबलेश्‍वरा एम.एस. ने कहा, “हमारा फोकस क्रेडिट विकास पर होने के नाते, बैंक एमएसएमई की फाइनेंसिंग में आगे रहता है। हम जेसीबी के साथ एमओयू पर हस्‍ताक्षर करके सचमुच खुश हैं, क्‍योंकि उत्‍कृष्‍टता, सत्‍यनिष्‍ठा और स्‍थायित्‍वपूर्ण विकास के हमारे मूल्‍य उनसे मिलते-जुलते हैं। हमारा बैंक अपने ग्राहकों को डिजिटल प्‍लेटफॉर्म के माध्‍यम से आकर्षक ब

*Reusable pads essential to make menstrual hygiene sustainable for all women and girls*

 If every woman and girl of menstruating age in India used disposable pads, 38,500,000,000 used pads would be discarded every month – an environmental disaster since each of these would take 500-800 years to degrade naturally XXX / May 26, 2021: Considering the immense non-biodegradable waste generated by disposable sanitary pads every month, sustainable menstrual hygiene in India can be achieved only with reusable pads made of organic material, said Anju Bist, Co-Director, Amrita SeRVe (Self Reliant Village) Program of Mata Amritanandamayi Math. Known as the “Pad Woman” of India for her zeal in promoting the use and reuse of sanitary pads made of cloth and banana fibre, she is the co-creator of Saukhyam Reusable Pads which have been awarded as the "Most Innovative Product" by the National Institute of Rural Development, Hyderabad. The pads were also lauded at the UN Climate Change Conference held in Poland in 2018. Said Anju Bist: “There are 355 million menstruating women an